Immunological Roles of CCL18 in Pan‑Cancer and Its Potential Value in Endometrial Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Inflammatory chemokine protein 18 (CCL18) is highly expressed in endometrial cancer (EC) and other cancers. This study identifies CCL18 as a potential prognostic biomarker for EC and suggests regulatory mechanisms involving SIX1, SOX3, and TWIST2.
Area Of Science
- Oncology
- Immunology
- Genetics
Background
- Endometrial cancer (EC) is a common female reproductive malignancy with unclear immune-related gene functions.
- The immune-related gene CCL18 is linked to tumor progression in various cancers, but its role in EC and pan-cancer is understudied.
Purpose Of The Study
- To investigate the expression, prognostic significance, and regulatory mechanisms of CCL18 in endometrial cancer (EC).
- To identify potential immune-related prognostic biomarkers for EC and explore therapeutic strategies.
Main Methods
- Utilized The Cancer Genome Atlas (TCGA), ImmPort, and Gene Expression Omnibus (GEO) databases.
- Performed immunohistochemistry on EC tissue chips.
- Analyzed microRNA sequencing and ATAC-seq data.
Main Results
- CCL18 expression was significantly elevated in EC tissues compared to normal endometrium.
- CCL18 demonstrated high expression across multiple cancer types, including EC and bladder cancer.
- SIX1, SOX3, and TWIST2 were identified as potential regulators of CCL18 transcription in EC.
Conclusions
- CCL18 is a potential prognostic biomarker for both pan-cancer and specifically for endometrial cancer.
- CCL18 presents a potential therapeutic target for EC treatment, with identified regulatory pathways.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.